Nearly one-quarter of research subjects with type 1 diabetes who had diabetic kidney disease showed signs of remission of their kidney disorder after beginning treatment with angiotensin-converter enzyme (ACE) inhibitors, say researchers at the Steno Diabetes Center in Gentofte, Denmark.
According to the November 2001 issue of Diabetes Care, Peter Hovind, MD, and colleagues aimed to evaluate the incidence of nephrotic-range albuminuria (NRA) and the frequency of remission in a group of 321 people with type 1 diabetes who also had diabetic kidney disease. The group was followed for three years.
NRA, defined as persistent albuminuria greater than 2,500 mg per 24 hours, was observed in 126 patients. The patients had an average type 1 duration of 22 years. Remission of NRA was defined as sustained albuminuria less than 600 mg per 24 hours for at least one year.
The cumulative incidence of NRA was 39 percent. Remission, which researchers describe as “characterized by slow progression of diabetic nephropathy and improved cardiovascular risk profile,” was induced in 28 of the 126 patients with NRA. The researchers note that 21 of these 28 people were treated predominantly with ACE inhibitors. Remission lasted an average of 3.6 years, and more women than men achieved remission.